Wedbush Downgrades Ikena Oncology to Neutral, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has downgraded Ikena Oncology (NASDAQ:IKNA) from Outperform to Neutral and lowered the price target from $8 to $2.
May 29, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wedbush analyst David Nierengarten downgraded Ikena Oncology from Outperform to Neutral and reduced the price target from $8 to $2.
The downgrade from Outperform to Neutral and the significant reduction in the price target from $8 to $2 by a reputable analyst is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100